Journal of Oncology Pharmacy Practice

AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360

Retrieved on: 
Tuesday, October 3, 2023
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, Janssen Pharmaceuticals, Disease, Journal of Oncology Pharmacy Practice, PharMerica, HRR, ADP, Abiraterone acetate, CI, National Cancer Institute, Janssen, ADT, Toxicity, Pharmacy, Prednisone, Death, BRCA2, Hospital, Specialty pharmacy, HIV disease progression rates, Patient, Risk, Testosterone, SEER, Johnson & Johnson, Gonadotropin-releasing hormone, BRCA, FDA, PARP, Orchiectomy, Phase, CYP17, Prostate cancer, Pharmaceutical industry, Epidemiology

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson for AKEEGA™ (niraparib and abiraterone acetate).

Key Points: 
  • Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson for AKEEGA™ (niraparib and abiraterone acetate).
  • Patients should be selected for therapy based on an FDA-approved test for AKEEGA.
  • Patients taking AKEEGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
  • “Onco360 is thankful for the opportunity to partner with the team at Janssen and become a specialty pharmacy provider for AKEEGA,” said Benito Fernandez, Chief Commercial Officer.

KRAZATI™ (adagrasib) Now Available from Onco360 for the Treatment of Adult Patients with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Thursday, December 15, 2022
Pharmaceutical, Health, Oncology, Other Health, Oncology, QT, Mirati, SEER, Diagnosis, Patient, United, Treatment of lung cancer, Diarrhea, NSCLC, FDA, Lung cancer, Fatigue, Hospital, RAS, PharMerica, Appetite, DOR, Large-cell lung carcinoma, Nausea, Vomiting, ORR, National Cancer Institute, Dizziness, Journal of Oncology Pharmacy Practice, Death, Specialty pharmacy, KRAS, Pharmaceutical industry, Epidemiology

Onco360 is honored to partner with Mirati Therapeutics and become a specialty pharmacy provider for KRAZATI patients, said Benito Fernandez, Chief Commercial Officer, Onco360.

Key Points: 
  • Onco360 is honored to partner with Mirati Therapeutics and become a specialty pharmacy provider for KRAZATI patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • We are dedicated to supporting the highly specialized needs of patients battling previously treated, advanced NSCLC with KRAS G12C mutations across the United States.
  • When considering all stages and histologic subtypes of lung cancer, five-year overall survival (OS) is only 22.9%.
  • Unfortunately, 56% of lung cancer patients already have metastatic disease upon initial diagnosis.

TIBSOVO® (ivosidenib) Now Available from Onco360 for the Treatment of Adult Patients with IDH1-mutant Acute Myeloid Leukemia or Previously Treated, IDH1-mutant Metastatic Cholangiocarcinoma

Retrieved on: 
Thursday, September 15, 2022
Biotechnology, FDA, Health, Pharmaceutical, Oncology, American Cancer Society, Specialty pharmacy, FDA, Cholangiocarcinoma, United, National Cancer Institute, PharMerica, SEER, Neoplasm, Patient, Journal of Oncology Pharmacy Practice, Acute myeloid leukemia, Diagnosis, Death, AML, Pharmacy, IDH1, Hospital, Mutation, Oncology, Azacitidine, Medical imaging, Epidemiology

Onco360 is honored to partner with Servier Pharmaceuticals and become a specialty pharmacy provider for TIBSOVO patients, said Benito Fernandez, Chief Commercial Officer, Onco360.

Key Points: 
  • Onco360 is honored to partner with Servier Pharmaceuticals and become a specialty pharmacy provider for TIBSOVO patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • We are dedicated to supporting the highly specialized needs of patients battling IDH1-mutant AML or cholangiocarcinoma across the United States.
  • The average age at the time of initial cholangiocarcinoma diagnosis is 70-72 years old dependent upon tumor location.
  • The five-year overall survival for cholangiocarcinoma patients, regardless of cancer stage, is only 9-10% dependent upon tumor location.3,4
    TIBSOVO is commercialized by Servier Pharmaceuticals.

VieCure Partners with Clarified Precision Medicine to Accelerate the Adoption of Precision Oncology

Retrieved on: 
Wednesday, August 10, 2022
Software, Biotechnology, Oncology, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Data integration, Multimedia, Adoption, Oncology, Founder, Journal of Oncology Pharmacy Practice, Precision medicine, Diagnosis, YouTube, Facebook, Nation, A.I, Precision, Informatics, Patient, Review, Clarify Op3nvoice, Degenerative disease, Center, Partnership, Artificial intelligence, Â, Solution, Collection, LinkedIn, Financial toxicity, Medical device, Medical imaging, Cancer

The Viecure-Clarified partnership offers a precision oncology expert version, where elite, expert precision medicine guidance can be accessed while using the Viecure clinical decision support platform.

Key Points: 
  • The Viecure-Clarified partnership offers a precision oncology expert version, where elite, expert precision medicine guidance can be accessed while using the Viecure clinical decision support platform.
  • The Clarified Precision Medicine team is an elite collection of experienced practicing precision medicine clinicians.
  • Clarified Precision Medicine is composed of nationally recognized talent in Medical Oncology, Oncology Pharmacy, Data Integration, Molecular Pathology with over 85 years in the application of Precision Oncology.
  • Clarified Precision Medicine offers expert clinical somatic and germline consultations through its Clarified Select and OncoGuardian solutions.

ORGOVYX® (relugolix) Now Available from Onco360 for the Treatment of Adult Patients with Advanced Prostate Cancer

Retrieved on: 
Monday, June 6, 2022
Oncology, Health, General Health, Radiology, Pharmaceutical, Biotechnology, Gonadotropin-releasing hormone, Death, Adult, ORGOVYX, Roivant Sciences, Prostate cancer, Food, United, Relugolix, Disease, National Cancer Institute, FDA, Male, Patient, Program, Hospital, SEER, Oncology, Pfizer, Diagnosis, Journal of Oncology Pharmacy Practice, PharMerica, Specialty pharmacy, Regulation of tobacco by the U.S. Food and Drug Administration, Malignancy, Cancer, Pharmaceutical industry, Medical imaging, Epidemiology

Onco360 is honored to become a specialty pharmacy provider for ORGOVYX patients, said Benito Fernandez, Chief Commercial Officer, Onco360.

Key Points: 
  • Onco360 is honored to become a specialty pharmacy provider for ORGOVYX patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • We are committed to supporting the highly specialized needs of patients battling advanced prostate cancer across the United States.
  • Prostate cancer is the most commonly diagnosed cancer in male patients.
  • Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers.

Simplivia Healthcare Unveils Latest Innovation in its Closed System Drug-Transfer Device Portfolio at the 2022 EAHP Conference

Retrieved on: 
Wednesday, March 16, 2022
Solution, Administration, Conference, FDA, Pharmacy, Nursing, Risk, CSTD, Prince Sultan Advanced Technology Research Institute, Safety, Journal of Oncology Pharmacy Practice, Canadian Society of Hospital Pharmacists, CE, Expert, Automatic exposure control, Workflow, Pharmaceutical industry, Medical device

Simplivia will launch Chemfort for the first time at the 26th Anniversary European Association of Hospital Pharmacists (EAHP) Conference.

Key Points: 
  • Simplivia will launch Chemfort for the first time at the 26th Anniversary European Association of Hospital Pharmacists (EAHP) Conference.
  • Simplivia introduce for the first time the Chemfort Closed Administration portfolio, which is designed for use by nurses when administering hazardous drugs.
  • "We are excited to showcase the Chemfort Closed system transfer device portfolio, which has received CE and FDA ONB product code," said Simplivia CEO Oded Grinstein.
  • For Simplivia activities at the EAHP 2022 please click here: https://simplivia.activetrail.biz/meet-us-EAHP
    Visit the EAHP website to learn more about the conference.

Simplivia Healthcare Unveils Latest Innovation in its Closed System Drug-Transfer Device Portfolio at the 2022 EAHP Conference

Retrieved on: 
Wednesday, March 16, 2022
Transfer, Solution, Administration, Conference, FDA, Pharmacy, Nursing, Risk, CSTD, Prince Sultan Advanced Technology Research Institute, Safety, Journal of Oncology Pharmacy Practice, Canadian Society of Hospital Pharmacists, CE, Expert, Automatic exposure control, Workflow, Pharmaceutical industry, Medical device

KIRYAT SHMONA, Israel, March 16, 2022 /PRNewswire/ -- Simplivia Healthcare Ltd., a leading global medical device developer, has announced the upcoming launch of Chemfort™, its newest closed system transfer device (CSTD). Chemfort™ reduces the risk of exposure for healthcare professionals when preparing and administering hazardous drugs.

Key Points: 
  • The company will showcase its latest Closed System Drug-Transfer Device, Chemfort, at this year's EAHP 26thAnniversary Conference
    KIRYAT SHMONA, Israel, March 16, 2022 /PRNewswire/ --Simplivia Healthcare Ltd., a leading global medical device developer, has announced the upcoming launch of Chemfort, its newest closed system transfer device (CSTD).
  • Simplivia will launch Chemfort for the first time at the 26th Anniversary European Association of Hospital Pharmacists (EAHP) Conference.
  • "We are excited to showcase the Chemfort Closed system transfer device portfolio, which has received CE and FDA ONB product code," said Simplivia CEO Oded Grinstein.
  • For Simplivia activities at the EAHP 2022 please click here: https://simplivia.activetrail.biz/meet-us-EAHP
    Visit the EAHP website to learn more about the conference.

B. Braun Medical Launches Next Generation OnGuard® 2 CSTD

Retrieved on: 
Thursday, December 2, 2021
Environment, Technology, Occupational safety and health, Health care, Use, Journal of Oncology Pharmacy Practice, NIOSH, MD, Pain management, Compounding, Corporation, Aerosol, B. Braun, National Institute, Patient safety, Medical Affairs Bureau, Research, Atmosphere, USP, CSTD, National Institute for Occupational Safety and Health, Journal, Company, CAPS, Multimedia, Dialysis, PMID, Medical device, Pharmaceutical industry, Television

BETHLEHEM, Pa., Dec. 2, 2021 /PRNewswire/ --B. Braun Medical Inc., a leading provider of closed system transfer devices (CSTD), announced today that the OnGuard 2 CSTD is now available in the United States.

Key Points: 
  • BETHLEHEM, Pa., Dec. 2, 2021 /PRNewswire/ --B. Braun Medical Inc., a leading provider of closed system transfer devices (CSTD), announced today that the OnGuard 2 CSTD is now available in the United States.
  • Only OnGuard 2 was tested with actual hazardous drugs for vapor containment and is the market leader in CSTD air-cleaning technology.
  • OnGuard 2 is manufactured by Simplivia Healthcare Ltd. and distributed by B. Braun Medical Inc. in the US.
  • B. Braun Medical is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap and CAPS.

EXKIVITY® (mobocertinib) Approved for Previously-Treated Adult Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Retrieved on: 
Wednesday, September 22, 2021
Pharmaceutical, Health, Oncology, Clinical trial, Program, National Cancer Institute, FDA, Patient, Death, Physician, Adult, Hospital, Oncology, Carroll C. Halterman, Lung cancer, NSCLC, Takeda, PharMerica, SEER, ORR, Large-cell lung carcinoma, Disease, Journal of Oncology Pharmacy Practice, PLOS One, NCI, EGFR, United, Lung, Vaccine, Pharmaceutical industry

Onco360 is excited to become a specialty pharmacy provider for EXKIVITY patients, said Benito Fernandez, Chief Commercial Officer, Onco360.

Key Points: 
  • Onco360 is excited to become a specialty pharmacy provider for EXKIVITY patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • As a provider of this important treatment option for patients, Onco360 is committed to supporting the highly specialized needs of locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutations and their physicians across the United States.
  • According to the National Cancer Institutes (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, approximately 235,760 patients will be diagnosed with lung cancer in 2021 with a corresponding 131,880 deaths.
  • When considering all subtypes of lung cancer as well as stages of the disease, lung cancer patients have a poor five-year overall survival (OS) of 21.7%.

Onco360® Selected by Merck & Co., Inc. to Be in Specialty Pharmacy Network for WELIREG™ (belzutifan)

Retrieved on: 
Thursday, August 19, 2021
Pharmaceutical, Health, Oncology, CNS, Merck & Co., RCC, Merck, Central nervous system, Pnet, Hospital, Adult, VHL, Patient, PharMerica, Neoplasm, Oncology, Journal of Oncology Pharmacy Practice, Pancreatic neuroendocrine tumor, Hemangioblastoma, Pharmaceutical industry

Onco360 is honored to be included in the Merck specialty pharmacy network for WELIREG, said Benito Fernandez, Chief Commercial Officer, Onco360.

Key Points: 
  • Onco360 is honored to be included in the Merck specialty pharmacy network for WELIREG, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • Onco360 is committed to supporting von Hippel-Lindau patients afflicted with certain associated tumors requiring treatment.
  • Onco360 is the largest independent Oncology Pharmacy and clinical support services company in the country.
  • Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States.